Literature DB >> 28777944

Human Pluripotent Stem Cell-Derived Atrial and Ventricular Cardiomyocytes Develop from Distinct Mesoderm Populations.

Jee Hoon Lee1, Stephanie I Protze2, Zachary Laksman3, Peter H Backx4, Gordon M Keller5.   

Abstract

The ability to direct the differentiation of human pluripotent stem cells (hPSCs) to the different cardiomyocyte subtypes is a prerequisite for modeling specific forms of cardiovascular disease in vitro and for developing novel therapies to treat them. Here we have investigated the development of the human atrial and ventricular lineages from hPSCs, and we show that retinoic acid signaling at the mesoderm stage of development is required for atrial specification. Analyses of early developmental stages revealed that ventricular and atrial cardiomyocytes derive from different mesoderm populations that can be distinguished based on CD235a and RALDH2 expression, respectively. Molecular and electrophysiological characterization of the derivative cardiomyocytes revealed that optimal specification of ventricular and atrial cells is dependent on induction of the appropriate mesoderm. Together these findings provide new insights into the development of the human atrial and ventricular lineages that enable the generation of highly enriched, functional cardiomyocyte populations for therapeutic applications.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD235a; PSCs; RALDH2; atrial; cardiovascular; differentiation; mesoderm; specification; ventricular

Mesh:

Substances:

Year:  2017        PMID: 28777944     DOI: 10.1016/j.stem.2017.07.003

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  133 in total

Review 1.  Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models.

Authors:  Alexa Wnorowski; Huaxiao Yang; Joseph C Wu
Journal:  Adv Drug Deliv Rev       Date:  2018-06-06       Impact factor: 15.470

Review 2.  Pluripotent Stem Cell-Derived Cardiomyocyte Transplantation for Heart Disease Treatment.

Authors:  Shin Kadota; Yuji Shiba
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

3.  Nkx2-5 defines a subpopulation of pacemaker cells and is essential for the physiological function of the sinoatrial node in mice.

Authors:  Hua Li; Dainan Li; Yuzhi Wang; Zhen Huang; Jue Xu; Tianfang Yang; Linyan Wang; Qinghuang Tang; Chen-Leng Cai; Hai Huang; Yanding Zhang; YiPing Chen
Journal:  Development       Date:  2019-07-25       Impact factor: 6.868

4.  In Vitro Generation of Heart Field-specific Cardiac Progenitor Cells.

Authors:  Emmanouil Tampakakis; Matthew Miyamoto; Chulan Kwon
Journal:  J Vis Exp       Date:  2019-07-03       Impact factor: 1.355

Review 5.  Intensive care for human hearts in pluripotent stem cell models.

Authors:  Pelin Golforoush; Michael D Schneider
Journal:  NPJ Regen Med       Date:  2020-03-06

Review 6.  Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation.

Authors:  Angelos Oikonomopoulos; Tomoya Kitani; Joseph C Wu
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

Review 7.  Applications of genetically engineered human pluripotent stem cell reporters in cardiac stem cell biology.

Authors:  Joe Z Zhang; Hongchao Guo; Joseph C Wu
Journal:  Curr Opin Biotechnol       Date:  2018-03-24       Impact factor: 9.740

Review 8.  Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.

Authors:  Emily A Pinheiro; Tarek Magdy; Paul W Burridge
Journal:  J Cardiovasc Transl Res       Date:  2020-02-20       Impact factor: 4.132

9.  Pluripotent Stem Cells for Cell Therapy.

Authors:  Insa S Schroeder
Journal:  Methods Mol Biol       Date:  2021

10.  Beyond Purple Hearts: A Colorful Approach to Isolate Distinct Heart Cells from Human iPSCs.

Authors:  Lauren N Randolph; Xiaojun Lance Lian
Journal:  Cell Stem Cell       Date:  2019-05-02       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.